Antenatal glucocorticoids supplementation and central nervous system development

Diego Gazzolo, Laura D. Serpero, Alessandro Frigiola, Raul Abella, Alessandro Giamberti, Giovanni Li Volti, Fabrizio Michetti

Research output: Contribution to journalArticlepeer-review

Abstract

Maternal antenatal therapy with glucocorticoids (GC) is routinely used to prevent lung immaturity. The potential harmful effects on other organs, including in particular the central nervous system (CNS), are still controversial. In the present review we aimed to investigate: i) the beneficial and detrimental effects of antenatal GC treatment in both human and animal models; ii) the potential usefulness of biochemical markers such as calcium binding proteins (S100B, synaptophysin) and cytoskeletal protein of neurons and dendrites (MAP2) in the perinatal period, and iii) whether the assessment of brain markers in different biological fluids could constitute a promising tool for the monitoring of CNS function and/or developmental in fetuses and newborns whose mothers assumed GC antenatally.

Original languageEnglish
Pages (from-to)160-166
Number of pages7
JournalCurrent Drug Metabolism
Volume14
Issue number2
Publication statusPublished - Feb 2013

Keywords

  • Cardiovascular
  • CNS
  • Glucocorticoids
  • MAP2
  • Prematurity
  • S100B
  • Synaptophysin

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Antenatal glucocorticoids supplementation and central nervous system development'. Together they form a unique fingerprint.

Cite this